Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Potassium guaiacolsulfonate is a small molecule expectorant and mucolytic agent used to alleviate symptoms of cough and chest congestion associated with respiratory tract infections, asthma, and the common cold. It functions through a physicochemical mechanism, acting directly on respiratory tract mucus to decrease its viscosity and stickiness. By thinning the phlegm, it facilitates more productive coughing and easier clearance of the airways. While it is frequently utilized as a component in multi-ingredient upper respiratory combination products alongside antitussives or other expectorants, it is a well-established generic compound with no single primary developer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on potassium guaiacolsulfonate.